BD Resumes ChloraPrep™ Shipments After Resolving FDA-Related Hold
BDX sits 16% above its 52-week low of $127.536.
Summary
Becton Dickinson announced the resumption of ChloraPrep™ shipments in the U.S. following additional release testing, confirming all tests were acceptable and no patient safety signals were identified.
Key Events · Legal and Risk Events · BDX
-
Shipments Resumed
Becton Dickinson has resumed shipments of ChloraPrep™ in the U.S.
-
Testing Acceptable
Additional final release testing for ChloraPrep™ has been completed and found acceptable.
-
No Patient Safety Signals
The company confirmed there have been no patient safety signals related to the products.
-
Resolution of Prior Hold
This action resolves the voluntary ship hold initiated on May 6, 2026, in response to an FDA Warning Letter for the El Paso manufacturing facility.
Analysis · BDX · Industrial Applications And Services
This filing provides a positive update on a previously disclosed product hold for ChloraPrep™ and PurPrep™ due to an FDA Warning Letter. The resumption of shipments and confirmation of no patient safety signals remove a regulatory overhang and mitigate potential revenue loss and reputational risk associated with the initial hold.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDX was trading at $148.41 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $40.9B. The 52-week trading range was $127.54 to $187.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.